|

Apalutamide Clinical Trials

19 actively recruiting trials across 12 locations

▲ +2 trials since May 2026

Also known as: ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927 +1 more

Pipeline

Phase 1: 2Phase 2: 8Phase 3: 7Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center2
  • Janssen Research & Development, LLC2
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
  • NRG Oncology1
  • Mayo Clinic1

Indications

  • Cancer19
  • Prostate Adenocarcinoma3
  • Metastatic Hormone-sensitive Prostate Cancer2
  • Biochemically Recurrent Prostate Carcinoma2
  • Stage IIIB Prostate Cancer AJCC V82

Other5 trials

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Phase 1/2
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Phase 2
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Phase 3
Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Anchorage, Alaska2 trials

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Anchorage Associates in Radiation Medicine

Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Anchorage Associates in Radiation Medicine

Phase 3

Phoenix, Arizona2 trials

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Mayo Clinic in Arizona

Phase 2
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Cancer Center at Saint Joseph's

Phase 3

Dothan, Alabama1 trial

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Research Site

Phase 3

Tucson, Arizona1 trial

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Banner University Medical Center - Tucson

Phase 3

Duarte, California1 trial

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

City of Hope

Phase 2

Los Angeles, California1 trial

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

Aurora, Colorado1 trial

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

University of Colorado Anschutz Medical Campus

Phase 1

Sarasota, Florida1 trial

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Florida Cancer Specialists

Phase 1

Tampa, Florida1 trial

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Moffitt Cancer Center

Phase 2

Chicago, Illinois1 trial

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Rush MD Anderson

Phase 3

Cleveland, Ohio1 trial

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company

Houston, Texas1 trial

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.